Preservatives in eye drops. Myths and realities
https://doi.org/10.21516/2072-0076-2025-18-4-157-163
Abstract
Preservatives in eye drops are an important ingredient that helps prevent microbial contamination of the drug and allow it to be used in an open bottle for a long time. Quaternary ammonium compounds are most often used for the purposes in question — benzalkonium chloride, cetrimonium chloride, etc. Chlorobutanol, chlorhexidine, thimerosal, methylparaben, sodium perborate, etc. have also found application. Numerous studies indicate the effectiveness and relative safety of eye drops containing a preservative in an acceptable dosage. In addition, there is information about the ability of preservatives to increase the penetration of drugs into the eye. At the same time, a certain toxicity of the listed preservatives serves as a limitation to their widespread use, especially in patients with destructive corneal pathology, when wearing contact lenses, etc. In this regard, preservatives have been developed that have sufficient antimicrobial activity “in a bottle”, in the absence of toxicity for the tissues of the ocular surface, including due to their decay to biologically inert compounds in the conjunctival cavity (under the influence of physical factors, enzymes of the lacrimal fluid, etc.): polyquad, oxide, purit, ocupur, SofZia, GenAqua, etc. A number of eye drops are now manufactured without preservatives at all (due to the special design of bottles or the use of single use dropper tubes). As clinical practice shows, preservative-free drugs are certainly preferable in the following situations: 1) the presence of dry eye syndrome in the patient or its development against the background of the use of drops with preservatives; 2) dystrophic or other diseases of the cornea or conjunctiva; 3) increased sensitivity of the ocular surface; 4) the need to wear soft contact lenses.
About the Authors
V. V. BrzheskiyRussian Federation
Vladimir V. Brzheskiy — Dr. of Med. Sci., professor, head of chair of ophthalmology
2, Litovskaya St., SaintPetersburg, 194100
G. G. Kim
Russian Federation
German G. Kim — PhD student, chair of ophthalmology
2, Litovskaya St., SaintPetersburg, 194100
A. Munawar
Russian Federation
Aldahruz Munawar — PhD student, chair of ophthalmology
2, Litovskaya St., SaintPetersburg, 194100
References
1. Baudouin C, Labb A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010; 29 (4): 312–34. https://doi.org/10.1016/j.preteyeres.2010.03.001
2. Morelli MK, Kloosterboer A, Omar AF. Pseudomonas aeruginosa corneal ulcer associated with artificial tears eye drops. JAMA Ophthalmol. 2023; 141 (5): 496. https://doi.org/10.1001/jamaophthalmol.2023.1105
3. Lawrence CA. Chemical preservatives for ophthalmic solutions. Am J Ophthalmol. 1955; 39 (3): 385–94. https://doi.org/10.1016/0002-9394(55)91285-x
4. Rosenthal RA, Buck SL, Henry CL, Schlech BA. Evaluation of the preserving efficacy of lubricant eye drops with a novel preservative system. J Ocul Pharmacol Ther. 2006; 22 (6): 440–8. https://doi.org/10.1089/jop.2006.22.440
5. Petrov S.Yu., Safonova D.M. Preservatives in ophthalmic preparations: from benzalkonium chloride to polyquaternium. Glaucoma. 2013; 12 (4): 82–96 (In Russ.).
6. Actis AG, Rolle T. Ocular surface alterations and topical antiglaucomatous therapy: A review. Open Ophthalmol J. 2014; 8: 67–72. https://doi.org/10.2174/1874364101408010067
7. Stalmans I, M gevand GS, Cordeiro MF, et al. Preservative-free treatment in glaucoma: who, when, and why? Eur J Ophthalmol. 2013; 23, 4: 518–25. https://doi.org/10.5301/ejo.5000270
8. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008; 86 (7): 716–26. https://doi.org/10.1111/j.1755-3768.2008.01250.x
9. Lebedev O.I., Kalizhnikova E.A., Yavorskij A.E. Mechanisms and effects of benzalkonium chloride on eye tissue. Klinicheskaya oftal'mologiya. 2013; 2: 63–79 (In Russ.).
10. Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009; 25 (2): 113–9. doi: 10.1089/jop.2008.0098
11. Brzheskiy V.V. Glaucoma and Dry Eye Syndrome. Moscow. OOO “Kompaniya BORGES”. 2018 (In Russ.).
12. Erb C. Glaucoma and dry eye. Bremen: “UNI-MED”, 2012.
13. P rez-Bartolom F, Mart nez-de-la-Casa JM, Arriola-Villalobos P, et al. Ocular surface disease in patients under topical treatment for glaucoma. Eur J Ophthalmol. 2017; 27 (6): 694–704. https://doi.org/10.5301/ejo.5000977
14. Alekseev V.N., Malevannaya O.A., Nader Samih El Hazh. Reasons for low adherence to treatment in patients with primary open-angle glaucoma. Oftal'mologicheskie vedomosti. 2010; 3 (4): 37–9 (In Russ.).
15. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctivaderived epithelial cells. Invest Ophthalmol Vis Sci. 2005; 46 (7): 2444–50. https://doi.org/10.1167/iovs.04-1331
16. Zimmerman TJ, Hahn SR, Gelb L. The effect of hyperaemia on open-angle glaucoma (OAG) treatment. Annual Meeting of the European Society of Ophthalmology (SOE), 9–12 June 2007, Vienna, Austria. Abstract FPGLA-036.
17. Nikolaenko V.P., Antonova A.V., Brzheskiy V.V. Ways to improve the effectiveness of glaucoma filtering surgery. Russian ophthalmological journal. 2024; 17 (2): 99–107 (In Russ.). https://doi.org/10.21516/2072-0076-2024-17-2-99-107
18. Baudouin C, Riancho L, Warnet J-M, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007; 48 (9): 4123–8. https://doi.org/10.1167/iovs.07-0266
19. Debbasch C, Brignole F, Pisella PJ, et al. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001; 42 (3): 642–52. https://doi.org/10.1016/s0002-9394(01)01036-4
20. Gobbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artifical tears. Ophthalmology. 1992; 99: 873–8. https://doi.org/10.1016/s0161-6420(92)31879-2
21. De Jong C, Stolwijk T, Kuppens E, Rob De Keizer R, Van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and auto uorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994; 232: 221–4. https://doi.org/10.1007/bf00184009
22. Rathore MS, Majumdar DK. Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS Pharm Sci Tech. 2006; 7: 57. https://doi.org/10.1208/pt070357
23. Majumdar S, Hippalgaonkar K, Repka MA. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm. 2008; 348: 175–8. https://doi.org/10.1016/j.ijpharm.2007.08.017
24. Yenice I, Mocan MC, Palaska E, et al. Hyaluronic acid coated polyepsiloncaprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp Eye Res. 2008; 87: 162–7. https://doi.org/10.1016/j.exer.2008.04.002
25. Valente C, Iester M, Corsi E, Rolando M. Symptoms and signs of tear film dysfunction in glaucomatous patients. J Ocul Pharmacol Ther. 2011; 27 (3): 281–5. https://doi.org/10.1089/jop.2010.0133
26. Pellinen P, Huhtala A, Tolonen A, et al. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. Current Eye Research. 2011; 37 (2): 145–54. https://doi.org/10.3109/02713683.2011.626909
27. Asada H, Takaoka-Shichijo Y, Nakamura M, Kimura A. Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy. Yakugaku Zasshi. 2010; 130 (6): 867–71. https://doi.org/10.1248/yakushi.130.867
28. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of Travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008; 2 (7): 339–43. https://doi.org/10.1097/ico.0b013e31815cf651
29. Larkin DFP, Kilvington ., Dart JKG. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology. 1992; 99: 185–91. https://doi.org/10.1016/s0161-6420(92)31994-3
30. Rozen S, Abelson M, Giovanoni A, Welch D. Assessment of the comfort and tolerance of 0.5% carboxymethylcellulose preserved with purite (Refresh Tears) in dry-eye suffers. Invest Ophthalmol Vis Sci. 1998; 39: S451.
31. Labb A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther. 2006; 22 (4): 267–8. https://doi.org/10.1089/jop.2006.22.267
32. Yilmaz FO, Sarmis A, Mutlu MA, et al. Bacterial contamination of multi-use tear drops, gels, and ointments. Contact Lens and Anterior Eye. 2023; 46 (6): 10206. https://doi.org/10.1016/j.clae.2023.102064
33. Asbell P, Potapova N. Effects of topical antiglaucoma medications on the ocular surface. Ocular Surface. 2005; 3 (1): 27–40. https://doi.org/10.1016/s1542-0124(12)70120-9
Review
For citations:
Brzheskiy V.V., Kim G.G., Munawar A. Preservatives in eye drops. Myths and realities. Russian Ophthalmological Journal. 2025;18(4):157-163. (In Russ.) https://doi.org/10.21516/2072-0076-2025-18-4-157-163


























